Volume | 261,263 |
|
|||||
News | - | ||||||
Day High | 0.606 | Low High |
|||||
Day Low | 0.56 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
TransCode Therapeutics Inc | RNAZ | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.606 | 0.56 | 0.606 | 0.587 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
587 | 261,263 | US$ 0.5864905 | US$ 153,228 | - | 0.42 - 309.60 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
11:52:35 | 1 | US$ 0.584 | USD |
TransCode Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
363.92k | 627.44k | - | 0 | -18.55M | -29.56 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
TransCode Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RNAZ Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.459 | 0.629 | 0.42 | 0.5478568 | 666,006 | 0.1249 | 27.21% |
1 Month | 0.6712 | 0.696 | 0.42 | 0.546111 | 473,589 | -0.0873 | -13.01% |
3 Months | 0.5621 | 0.76 | 0.42 | 0.6249813 | 405,200 | 0.0218 | 3.88% |
6 Months | 12.80 | 19.424 | 0.42 | 7.63 | 1,625,536 | -12.22 | -95.44% |
1 Year | 254.16 | 309.60 | 0.42 | 33.40 | 2,284,480 | -253.58 | -99.77% |
3 Years | 4,800.00 | 5,600.00 | 0.42 | 1,003.10 | 1,716,881 | -4,799.42 | -99.99% |
5 Years | 4,800.00 | 5,600.00 | 0.42 | 1,003.10 | 1,716,881 | -4,799.42 | -99.99% |
TransCode Therapeutics Description
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. |